M&A Update – Jan 20

– RAPT to be acquired by GSK for $58.00 cash per share, 65.2% premium, $1.9 billion
– WBD / NFLX revised transaction to $27.75 + Discovery Global spin-off, filed PREM14a, filed HSR Dec 17, received second request from DOJ Jan 16
– FYBR / VZ deal closed
– CMA / FITB filed delisting notice, closing Feb 2
– NGD / CDE announced Glass Lewis recommends vote For
– ECN vote
– BHF HSR expires
– SEMR HSR expires